Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 18/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1590195 | 0.94 | PTGER4 (0.41) | PTGER4CYP1A2CYP2D6NPC1TP53 | |
| SCHEMBL1590220 | 0.94 | PTGER4 (0.43) | PTGER4CYP1A2CYP2D6NPC1TP53 | |
| SCHEMBL2302346 | 0.94 | PTGER4 (0.40) | PTGER4CYP1A2CYP2D6NPC1TP53 | |
| SCHEMBL2298844 | 0.89 | PTGER4 (0.39) | PTGER4CYP1A2CYP2D6NPC1TP53 | |
| SCHEMBL1591333 | 0.88 | PTGER4 (0.38) | PTGER4CYP1A2CYP2D6NPC1TP53 | |
| SCHEMBL1591995 | 0.86 | PTGER4 (0.37) | PTGER4CYP1A2CYP2D6NPC1TP53 | |
| SCHEMBL1591783 | 0.86 | PTGER4 (0.37) | PTGER4CYP1A2CYP2D6NPC1TP53 | |
| SCHEMBL2299588 | 0.84 | PTGER4 (0.42) | PTGER4CYP1A2CYP2D6PTGS1PTGS2 | |
| SCHEMBL2297646 | 0.84 | PTGER4 (0.57) | PTGER4CYP1A2CYP2D6 | |
| SCHEMBL4611048 | 0.83 | PTGER4 (0.66) | PTGER4CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201663-A1 | BENZO (F) ISOINDOL-2-YLPHENYL ACETIC ACID DERIVATIVES AS EP4 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201663-A1 | BENZO (F) ISOINDOL-2-YLPHENYL ACETIC ACID DERIVATIVES AS EP4 RECEPTOR AGONISTS | PTGER4, PTGER1, PTGER2 | PTGER4 1/4885CYP1A2 284/4885CYP2D6 447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.